Relmada Therapeutics (RLMD) Total Non-Current Liabilities (2014 - 2018)

Relmada Therapeutics (RLMD) has 5 years of Total Non-Current Liabilities data on file, last reported at $4.4 million in Q2 2018.

• On a quarterly basis, Total Non-Current Liabilities rose 263.64% year-over-year to $4.4 million in Q2 2018; TTM through Jun 2018 was $4.4 million, a 263.64% increase from a year earlier, with the FY2018 full-year figure at $4.4 million, up 263.64% from the prior year.
• Total Non-Current Liabilities for Q2 2018 stood at $4.4 million, up from $1.2 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for RLMD reached as high as $28.1 million in Q4 2014 and fell as low as $1.2 million in Q2 2017.
• Historically, Total Non-Current Liabilities has averaged $6.5 million across 5 years, with a median of $2.2 million in 2016.
• Across the five-year window, Total Non-Current Liabilities slumped 90.48% in 2016 and soared 263.64% in 2018, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $28.1 million in 2014, then sank by 94.37% to $1.6 million in 2015, then declined by 10.63% to $1.4 million in 2016, then slipped by 15.03% to $1.2 million in 2017, then surged by 263.64% to $4.4 million in 2018.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $4.4 million in Q2 2018, $1.2 million in Q2 2017, and $1.2 million in Q1 2017.